Printer Friendly

T CELL SCIENCES REPORTS NEW DATA ON sCR1

 T CELL SCIENCES REPORTS NEW DATA ON sCR1
 CAMBRIDGE, Mass., March 3 /PRNewswire/ -- T Cell Sciences, Inc.


(NASDAQ: TCEL), today reported that a protein being developed as the company's first therapeutic product significantly reduced tissue injury in several animal models of inflammation.
 The protein, sCR1, limited tissue injury by reducing neutrophil content in the area of inflammation in these animal models by at least 68 percent. These results support possible use of sCR1 in human disease conditions in which similar inflammatory events occur, such as adult respiratory distress syndrome (ARDS), complications of cardiopulmonary bypass, and renal disease.
 The results of this study are reported in a paper appearing in the current issue of the Journal of Immunology. Previously, sCR1 has been the subject of several published studies showing the protein's ability to limit complement-mediated inflammatory tissue damage that occurs in heart reperfusion (the re-establishment of blood flow to the heart following a period of ischemia), and allograft (same species) and xenograft (cross-species) organ transplantation. T Cell Sciences continues additional animal studies to evaluate the protective effects of sCR1 in several inflammatory conditions.
 "At this time physicians do not have any practical way to treat complement-mediated inflammatory tissue damage which occurs in many medical conditions," commented Alfred Rudolph, M.D., senior vice president of T Cell Sciences. "Based on the results seen in animals, we are very encouraged by the development of this product to date." CR1 is a human regulatory protein of the complement system that functions to depress complement-mediated inflammatory signals. sCR1 is a recombinantly produced modified version of the naturally occurring protein which can be administered to reduce tissue damage.
 The published study, "Protective Effects of Soluble CR1 in Complement and Neutrophil-mediated Tissue Injury," was authored by scientists Grace Yeh and Alfred Rudolph of T Cell Sciences, and Michael Mulligan and Peter Ward of the University of Michigan Medical School.
 Located in Cambridge, Mass., T Cell Sciences, Inc., is utilizing proprietary T cell receptor and soluble receptor technology to develop pharmaceutical products to treat heart disease, inflammatory diseases, autoimmune diseases and cancer. T Cell Diagnostics, Inc., a subsidiary of T Cell Sciences, develops, manufactures and markets products for monitoring immune system disorders.
 -0- 3/3/92
 /CONTACT: Alfred R. Rudolph, M.D., senior vice president, or Susan Primrose of T Cell Sciences, 617-621-1400/
 (TCEL) CO: T Cell Sciences, Inc. ST: Massachusetts IN: MTC SU:


GK -- NY027 -- 4369 03/03/92 09:41 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 3, 1992
Words:405
Previous Article:HEMODYNAMICS ANNOUNCES OFFERING BY PROTECTIVE APPAREL CORPORATION
Next Article:AMERICAN PACIFIC CORP. ANNOUNCES FILING OF REGISTRATION STATEMENT
Topics:


Related Articles
T CELL SCIENCES REPORTS FISCAL YEAR 1992 FINANCIAL RESULTS
T CELL SCIENCES REPORTS FIRST QUARTER RESULTS
ONCOGENE SCIENCE, INC. REPORTS FIRST QUARTER RESULTS
T CELL SCIENCES REPORTS 1992 FINANCIAL RESULTS; FIGURES REFLECT CHANGE TO CALENDAR YEAR END
sCR1 CLINICAL DEVELOPMENT TRANSFERRED TO T CELL SCIENCES
AVANT Immunotherapeutics Receives Key Patent for its Targeted, Second Generation Complement Inhibitor.
AVANT'S Hybrid Complement-Selectin Inhibitor, TP20, Significantly Limits Brain Damage in an Animal Model of Ischemic Stroke.
AVANT Receives Patent for Use of its Targeted, Second Generation Complement Inhibitor TP20 in Stroke.
CuraGen Reports First Quarter 2005 Results; -- PXD101 enters Phase II clinical trial for multiple myeloma --.
CEL-SCI files patent application to support company's treatment for more virulent strain of H1N1 swine and other influenza viruses.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters